A Phase 2 interventional study of bevacizumab [Avastin] and Interferon alfa-2a in Renal Cell Cancer, sponsored by Hoffmann-La Roche. Completed at 16 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-13.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing bevacizumab in Carcinoma, Renal Cell — 1 open to participants now, 3 under way, none of them phase 3. Bevacizumab · Carcinoma, Renal Cell.
Among the 44 studies testing bevacizumab in Carcinoma, Renal Cell, this one is the 32nd largest by enrollment, is one of 5 that started in 2007, is one of 25 in phase 2, and was the 14th registered.
2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.
Browse Carcinoma, Renal Cell studies →1 of the 44 studies testing bevacizumab in Carcinoma, Renal Cell is open now, in 1 country. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 12+
By country, each count listing its studies:
Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →
Of the 307 Carcinoma, Renal Cell studies recruiting now, 254 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 20 take children under 18; 19 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 31 · Phase 3 5
First in 2003; this study’s year is marked. 5 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 25 is below the median of 43 across 1,565 interventional studies indexed under Carcinoma, Renal Cell.
Median enrollment 46 across the 44 interventional studies. Of the 32 that completed or were terminated, 19 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 44 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
25 studies in Carcinoma, Renal Cell by Hoffmann-La Roche: none open now, 3 under way, none of them phase 3. Of 20 finished, 11 (55%) have results posted.
Among the 25 studies in Carcinoma, Renal Cell by Hoffmann-La Roche, this one is the 14th largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2007, is one of 9 in phase 2, and was the 4th registered.
Hoffmann-La Roche’s Carcinoma, Renal Cell studies by the year they started, since 2004.
1 of the studies testing bevacizumab in Carcinoma, Renal Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01684397Roswell Park Cancer InstitutePazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer | 2027-02-20 |
Add it to your calendar (.ics) → With an account.
Among the 44 studies testing bevacizumab in Carcinoma, Renal Cell, from their registry updates:
Among Hoffmann-La Roche’s 25 in Carcinoma, Renal Cell:
This tab as a report to print or save as PDF → With an account.
This single arm study will assess the efficacy and safety of Avastin in combination with interferon alfa-2a and vinblastine as first line treatment in patients with metastatic renal cell cancer. Patients will receive Avastin (15mg/kg iv) every 3 weeks, interferon alfa-2a 3 times weekly (3 Mio IU sc escalating to 18 Mio sc) and vinblastine (0.1mg/kg iv) every 3 weeks. The anticipated time on study treatment is until tumor progression, and the target sample size is 100-500 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: bevacizumab [Avastin] · Drug: Interferon alfa-2a · Drug: Vinblastine
15mg/kg iv every 3 weeks
3 MioIU sc escalating to 18 MioIU sc, 3 times weekly
0.1mg/kg iv every 3 weeks
Percentage of Participants With Disease Progression or Death
Disease progression was evaluated according to the Response Evaluation Criteria In Solid Tumors (RECIST) using computed tomography (CT) scans (preferred method), magnetic resonance imaging (MRI) scans, X-ray, bone scans, or clinical examination.
Time frame: Days 0, 91, 182, 273, 365, 456, and 547
PFS - Time to Event
PFS was defined as the time in days from the date of treatment start to the date of first documented disease progression or death. Disease progression was evaluated according to RECIST using CT scans (preferred method), MRI scans, X-ray, bone scans, or clinical examination. Median PFS was estimated using the Kaplan-Meier method
Time frame: Days 0, 91, 182, 273, 365, 456, and 547
Percentage of Participants With Objective Response (OR)
Percentage of participants with OR based on assessment of confirmed complete remission (CR) or confirmed partial remission (PR) according to RECIST.
Time frame: Baseline and Cycles 3, 6, 9, 13, and 17
Overall Survival (OS)
OS was defined as the duration from treatment start to death from any cause. Overall survival was censored at the last contact for surviving participants and missing data points.
Time frame: Baseline, Day 1 of every cycle to disease progression or death (up to Week 102)
| Milestone | Bevacizumab + Interferon Alfa-2a (IFN)/Vinblastine |
|---|---|
| Started | 25 |
| Completed | 7 |
| Not completed | 18 |
| Withdrew: Radiological progression of cancer | 6 |
| Withdrew: Adverse event | 4 |
| Withdrew: Withdrawal of consent | 4 |
| Withdrew: Death | 2 |
| Withdrew: Discontinuation of study/background drug | 1 |
| Withdrew: Protocol deviation affecting safety | 1 |
| Milestone | Bevacizumab + Interferon Alfa-2a (IFN)/Vinblastine |
|---|---|
| Started | 2 |
| Completed | 0 |
| Not completed | 2 |
| Withdrew: Radiological progression of cancer | 1 |
| Withdrew: Symptomatic progression of cancer | 1 |
Disease progression was evaluated according to the Response Evaluation Criteria In Solid Tumors (RECIST) using computed tomography (CT) scans (preferred method), magnetic resonance imaging (MRI) scans, X-ray, bone scans, or clinical examination.
| percentage of participants | Bevacizumab + IFN/Vinblastine |
|---|---|
| Percentage of Participants With Disease Progression or Death | 66.9 |
Percentage of participants with OR based on assessment of confirmed complete remission (CR) or confirmed partial remission (PR) according to RECIST.
| percentage of participants | Bevacizumab + IFN/Vinblastine |
|---|---|
| Week 9 (n=14) | 21.4 |
| Week 18 (n=16) | 31.3 |
| Week 27 (n=16) | 37.5 |
| Week 39 (n=16) | 31.3 |
| Week 51 (n=16) | 31.3 |
OS was defined as the duration from treatment start to death from any cause. Overall survival was censored at the last contact for surviving participants and missing data points.
| weeks | Bevacizumab + IFN/Vinblastine |
|---|---|
| Overall Survival (OS) | NA (NA to NA) |
PFS was defined as the time in days from the date of treatment start to the date of first documented disease progression or death. Disease progression was evaluated according to RECIST using CT scans (preferred method), MRI scans, X-ray, bone scans, or clinical examination. Median PFS was estimated using the Kaplan-Meier method
| days | Bevacizumab + IFN/Vinblastine |
|---|---|
| PFS - Time to Event | 274 ± 31.6 |
Collected over From treatment start to 28 days after treatment cessation in the regular treatment period only (Cycles 1 through 17; bevacizumab + IFN/vinblastine). Does not include AEs reported during bevacizumab monotherapy (Cycles 18 and beyond).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bevacizumab + IFN/Vinblastine | — | 8/25 (32%) | 22/25 (88%) |
| Event | Bevacizumab + IFN/Vinblastine |
|---|---|
| NeutropeniaBlood and lymphatic system disorders | 1/25 |
| Abdominal PainGastrointestinal disorders | 1/25 |
| NauseaGastrointestinal disorders | 1/25 |
| VomitingGastrointestinal disorders | 1/25 |
| Chest PainGeneral disorders | 1/25 |
| General Physical Health DeteriorationGeneral disorders | 1/25 |
| Injection Site ReactionGeneral disorders | 1/25 |
| Systemic Inflammatory Response SyndromeGeneral disorders | 1/25 |
| DehydrationMetabolism and nutrition disorders | 1/25 |
| Cerebral HaemorrhageNervous system disorders | 1/25 |
| Event | Bevacizumab + IFN/Vinblastine |
|---|---|
| FatigueGeneral disorders | 10/25 |
| AnorexiaMetabolism and nutrition disorders | 10/25 |
| ProteinuriaRenal and urinary disorders | 8/25 |
| NauseaGastrointestinal disorders | 7/25 |
| Influenza like illnessGeneral disorders | 6/25 |
| HeadacheNervous system disorders | 6/25 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 6/25 |
| HypertensionVascular disorders | 6/25 |
| ChillsGeneral disorders | 5/25 |
| Mucosal inflammationGeneral disorders | 4/25 |
Safety Population: included all participants, even those who withdrew from the study prematurely and who received at least 1 dose of bevacizumab and had a safety follow-up visit.
| Age, Continuous(years) | Bevacizumab + IFN/Vinblastine |
|---|---|
| Mean | 62.2 ± 8.5 |
| Sex: Female, Male(Participants) | Bevacizumab + IFN/Vinblastine |
|---|---|
| Female | 4 |
| Male | 21 |
The record gives a start of Sep 2007, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 4 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bevacizumab · Interferon alpha-2 · Vinblastine